Search

Your search keyword '"Bjermer, L"' showing total 919 results
Start Over Author "Bjermer, L"
919 results on '"Bjermer, L"'

201. Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN

Author

Carlsen, Kh, Anderson, Sd, Bjermer, L, Bonini, S, Brusasco, Vito, Canonica, Giorgio, Cummiskey, J, Delgado, L, DEL GIACCO SR, Drobnic, F, Haahtela, T, Larsson, K, Palange, P, Popov, T, VAN CAUWENBERGE, P, EUROPEAN RESPIRATORY SOCIETY, and EUROPEAN ACADEMY OF ALLERGY AND CLINICAL IMMUNOLOGY

Published
2008

206. Inducible nitric oxide synthase expression is increased in the alveolar compartment of asthmatic patients.

Author

Tufvesson, E., Andersson, C., Weidner, J., Erjefält, J. S., and Bjermer, L.

Subjects
ASTHMA diagnosis, NITRIC oxide, GENE expression, INFLAMMATION, BRONCHIAL diseases
Abstract

Introduction Increased exhaled nitric oxide ( NO) levels in asthma are suggested to be through inducible NO synthase (i NOS). The aim of this study was to investigate the expression of i NOS in bronchoalveolar lavage ( BAL) cells and tissue from central and peripheral airways and compare it with the exhaled bronchial and alveolar NO levels in patients with asthma vs a control group. Methods Thirty-two patients with asthma (defined as controlled or uncontrolled according to Asthma Control Test score cut-off: 20) and eight healthy controls were included. Exhaled NO was measured, and alveolar concentration and bronchial flux were calculated. i NOS was measured in central and peripheral lung biopsies, as well as BAL cells. Bronchoalveolar lavage macrophages were stimulated in vitro, and i NOS expression and NO production were investigated. Results Expression of i NOS was increased in central airway tissue and the alveolar compartment in uncontrolled as compared to controlled asthmatics and healthy controls. There were no differences, however, in i NOS m RNA levels in total BAL cells in uncontrolled as compared to controlled asthma. Bronchoalveolar lavage cell m RNA levels of i NOS or i NOS expression in central and alveolar tissue did not relate to alveolar NO, nor to bronchial flux of NO. In vitro stimulation with leukotriene D4 increased i NOS m RNA levels and NO production in cultured BAL macrophages. Conclusion The levels of both bronchial and alveolar i NOS are increased in uncontrolled as compared to controlled asthma. However, levels of i NOS in BAL macrophages were not reflected by alveolar NO. Both central and distal i NOS levels may reflect responsiveness to steroid treatment. [ABSTRACT FROM AUTHOR]

Published
2017
Full Text
View/download PDF

207. P256 Safety Of Once-daily Tiotropium And Olodaterol Fixed-dose Combination Via The Respimat In Chronic Obstructive Pulmonary Disease In Two 1-year Studies

Author

Buhl, R., primary, Abrahams, R., additional, Bjermer, L., additional, Derom, E., additional, Fle ar, M., additional, Hebert, J., additional, Veale, A., additional, Gronke, L., additional, Hamilton, A., additional, Tetzlaff, K., additional, Korducki, L., additional, Huisman, H., additional, Waitere-Wijker, S., additional, and McGarvey, L., additional

Published
2014
Full Text
View/download PDF

209. Modulation of allergen-induced bronchoconstriction by fluticasone furoate and vilanterol alone or in combination

Author

Oliver, A, Bjermer, L, Quinn, D, Saggu, P, Thomas, P, Yarnall, K, Lötvall, J, Oliver, A, Bjermer, L, Quinn, D, Saggu, P, Thomas, P, Yarnall, K, and Lötvall, J

Abstract

Background This placebo-controlled study assessed the effects of the once-daily inhaled corticosteroid (ICS) fluticasone furoate (FF) and long-acting beta2-agonist (LABA) vilanterol (VI) on early and late asthmatic responses (EAR/LAR) and airway hyper-responsiveness (AHR). Methods Patients (n = 27) were randomized to FF (100 μg), VI (25 μg), FF/VI (100/25 μg), and placebo for 21 days (four periods). Allergen challenge was performed 1 h post-dose on day 21. AHR was assessed on day 22 using methacholine. Results Allergen challenge caused an early change (0-2 h) in minimum forced expiratory volume in 1 s (FEV1) of -1.091 l (95% CI: -1.344; -0.837) following placebo therapy; changes were -0.955 l (-1.209; -0.702), -0.826 l (-1.070; -0.581), and -0.614 l (-0.858; -0.370) following VI, FF, or FF/VI therapy, respectively. Treatment differences were significant for all comparisons between therapies. Mean changes in 0-2 h %FEV1 were as follows: -28.05 (placebo), -23.10 (VI), -22.33 (FF), and -16.10 (FF/VI). Following placebo, the late change (4-10 h) in weighted mean FEV1 was -0.466 l (-0.589; -0.343) and -0.298 l (-0.415; -0.181) after VI, and was +0.018 l with both FF/VI (-0.089; 0.124) and FF (-0.089; 0.125). Treatment differences were significant for all comparisons between therapies except FF/VI vs FF. Mean changes in 4-10 h %FEV1 were as follows: -21.08 (placebo), -14.30 (VI), -5.02 (FF), and -5.83 (FF/VI). AHR 24 h after allergen challenge was significantly reduced with FF/VI and FF vs placebo, and FF/VI was superior to either component. Conclusion Combined treatment with FF/VI provides additive protection from the EAR relative to its components, significant protection over VI alone from the LAR, and confers sustained protection from hyper-responsiveness 24 h post-dose. © 2013 The Authors. Allergy published by John Wiley & Sons Ltd.

Published
2013

210. Nocturnal temperature controller laminar airflow for treating atopic asthma : a randomised controlled trial

Author

Boyle, R J, Pedroletti, C, Wickman, M, Bjermer, L, Valovirta, E, Dahl, R, Von Berg, A, Zetterström, Olle, Warner, J O, Boyle, R J, Pedroletti, C, Wickman, M, Bjermer, L, Valovirta, E, Dahl, R, Von Berg, A, Zetterström, Olle, and Warner, J O

Abstract

Objective To determine whether environmental control using nocturnal temperature controlled laminar airflow (TLA) treatment could improve the quality of life of patients with persistent atopic asthma. Design Randomised, double-blind, placebo-controlled, parallel-group trial. Setting Nineteen European asthma clinics. Participants 312 patients aged 7-70 with inadequately controlled persistent atopic asthma. Main outcome measure Proportion of patients with an increase of >= 0.5 points in asthma quality of life score after 1 year of treatment. Results TLA devices were successfully installed in the bedrooms of 282 (90%) patients included in the primary efficacy analysis. There was a difference in treatment response rate between active (143 of 189, 76%) and placebo (56 of 92, 61%) groups, difference 14.8% (95% CI 3.1 to 26.5, p=0.02).(3) In patients aged >= 12, on whom the study was powered, the difference in response rate was similar-active 106 of 143 (74%), placebo 42 of 70 (60%), difference 14.1% (0.6 to 27.7, p=0.059). There was a difference between groups in fractional exhaled nitric oxide change of -7.1 ppb (-13.6 to -0.7, p=0.03). Active treatment was associated with less increase in cat-specific IgE than placebo. There was no difference in adverse event rates between treatment groups. Conclusion Inhalant exposure reduction with TLA improves quality of life, airway inflammation and systemic allergy in patients with persistent atopic asthma. TLA may be a treatment option for patients with inadequately controlled persistent atopic asthma., funding agencies|Airsonett AB||National Institute for Health Research||National Institute for Health Research Biomedical Research Centre||MRC||Asthma UK Centre in Allergic Mechanisms of Asthma

Published
2012
Full Text
View/download PDF

211. Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology

Author

Bousquet, J. Hellings, P.W. Agache, I. Amat, F. Annesi-Maesano, I. Ansotegui, I.J. Anto, J.M. Bachert, C. Bateman, E.D. Bedbrook, A. Bennoor, K. Bewick, M. Bindslev-Jensen, C. Bosnic-Anticevich, S. Bosse, I. Brozek, J. Brussino, L. Canonica, G.W. Cardona, V. Casale, T. Cepeda Sarabia, A.M. Chavannes, N.H. Cecchi, L. Correia de Sousa, J. Costa, E. Cruz, A.A. Czarlewski, W. De Carlo, G. De Feo, G. Demoly, P. Devillier, P. Dykewicz, M.S. El-Gamal, Y. Eller, E.E. Fonseca, J.A. Fontaine, J.-F. Fokkens, W.J. Guzmán, M.-A. Haahtela, T. Illario, M. Ivancevich, J.-C. Just, J. Kaidashev, I. Khaitov, M. Kalayci, O. Keil, T. Klimek, L. Kowalski, M.L. Kuna, P. Kvedariene, V. Larenas-Linnemann, D. Laune, D. Le, L.T.T. Carlsen, K.L. Lourenço, O. Mahboub, B. Mair, A. Menditto, E. Milenkovic, B. Morais-Almeida, M. Mösges, R. Mullol, J. Murray, R. Naclerio, R. Namazova-Baranova, L. Novellino, E. O'Hehir, R.E. Ohta, K. Okamoto, Y. Okubo, K. Onorato, G.L. Palkonen, S. Panzner, P. Papadopoulos, N.G. Park, H.-S. Paulino, E. Pawankar, R. Pfaar, O. Plavec, D. Popov, T.A. Potter, P. Prokopakis, E.P. Rottem, M. Ryan, D. Salimäki, J. Samolinski, B. Sanchez-Borges, M. Schunemann, H.J. Sheikh, A. Sisul, J.-C. Rajabian-Söderlund, R. Sooronbaev, T. Stellato, C. To, T. Todo-Bom, A.-M. Tomazic, P.-V. Toppila-Salmi, S. Valero, A. Valiulis, A. Valovirta, E. Ventura, M.-T. Wagenmann, M. Wang, D.Y. Wallace, D. Waserman, S. Wickman, M. Yorgancioglu, A. Zhang, L. Zhong, N. Zidarn, M. Zuberbier, T. Aberer, W. Akdis, C.A. Akdis, M. Alberti, M.R. Almeida, R. Angles, R. Arnavielle, S. Asayag, E. Asarnoj, A. Arshad, H. Avolio, F. Bacci, E. Baiardini, I. Barbara, C. Barbagallo, M. Baroni, I. Barreto, B.A. Basagana, X. Bedolla-Barajas, M. Beghé, B. Bel, E.H. Bergmann, K.C. Benson, M. Bertorello, L. Białoszewski, A.Z. Bieber, T. Bialek, S. Bjermer, L. Blain, H. Blasi, F. Blua, A. Bochenska Marciniak, M. Bogus-Buczynska, I. Boner, A.L. Bonini, M. Bonini, S. Bouchard, J. Boulet, L.P. Bourret, R. Braido, F. Briedis, V. Brightling, C.E. Bucca, C. Buhl, R. Buonaiuto, R. Panaitescu, C. Burguete Cabañas, M.T. Burte, E. Bush, A. Caballero-Fonseca, F. Caillot, D. Caimmi, D. Calderon, M.A. Camargos, P.A.M. Camuzat, T. Canfora, G. Carreiro-Martins, P. Carriazo, A.M. Carr, W. Cartier, C. Castellano, G. Chen, Y. Chiron, R. Chivato, T. Chkhartishvili, E. Chuchalin, A.G. Chung, K.F. Ciaravolo, M.M. Ciceran, A. Cingi, C. Ciprandi, G. Carvalho Coehlo, A.C. Colas, L. Colgan, E. Coll, J. Conforti, D. Cortés-Grimaldo, R.M. Corti, F. Costa-Dominguez, M.C. Courbis, A.L. Cox, L. Crescenzo, M. Custovic, A. Dahlen, S.E. Dario, C. da Silva, J. Dauvilliers, Y. Darsow, U. De Blay, F. Dedeu, T. de Fátima Emerson, M. De Vries, G. De Martino, B. de Paula Motta Rubini, N. Deleanu, D. Denburg, J.A. Di Capua Ercolano, S. Di Carluccio, N. Didier, A. Dokic, D. Dominguez-Silva, M.G. Douagui, H. Dray, G. Dubakiene, R. Durham, S.R. Du Toit, G. Eklund, P. Emuzyte, R. Farrell, J. Farsi, A. Ferreira de Mello, J. Ferrero, J. Fink-Wagner, A. Fiocchi, A. Forti, S. Fuentes-Perez, J.M. Gálvez-Romero, J.L. Gamkrelidze, A. Garcia-Aymerich, J. García-Cobas, C.Y. Garcia-Cruz, M.H. Gemicioğlu, B. Genova, S. George, C. Gereda, J.E. Gerth van Wijk, R. Gomez, R.M. Gómez-Vera, J. González Diaz, S. Gotua, M. Grisle, I. Guidacci, M. Guldemond, N.A. Gutter, Z. Hajjam, J. Hernández, L. Hourihane, J.O. Huerta-Villalobos, Y.R. Humbert, M. Iaccarino, G. Jares, E.J. Jassem, E. Johnston, S.L. Joos, G. Jung, K.S. Jutel, M. Kalyoncu, A.F. Karjalainen, J. Kardas, P. Keith, P.K. Khaltaev, N. Kleine-Tebbe, J. Kuitunen, M. Kull, I. Kupczyk, M. Krzych-Fałta, E. Lacwik, P. Lauri, D. Lavrut, J. Lessa, M. Levato, G. Li, J. Lieberman, P. Lipiec, A. Lipworth, B. Lodrup Carlsen, K.C. Louis, R. Luna-Pech, J.A. Maciej, K. Magnan, A. Maier, D. Majer, I. Malva, J. Mandajieva, E. Manning, P. De Manuel Keenoy, E. Marshall, G.D. Masjedi, M.R. Maspero, J.F. Mathieu-Dupas, E. Matta Campos, J.J. Matos, A.L. Maurer, M. Mavale-Manuel, S. Mayora, O. Medina-Avalos, M.A. Melén, E. Melo-Gomes, E. Meltzer, E.O. Mercier, J. Miculinic, N. Mihaltan, F. Moda, G. Mogica-Martinez, M.D. Mohammad, Y. Momas, I. Montefort, S. Monti, R. Mora Bogado, D. Morato-Castro, F.F. Mota-Pinto, A. Moura Santo, P. Münter, L. Muraro, A. Nadif, R. Nalin, M. Napoli, L. Neffen, H. Niedeberger, V. Nekam, K. Neou, A. Nieto, A. Nogueira-Silva, L. Nogues, M. Nyembue, T.D. Odzhakova, C. Ortega Cisneros, M. Ouedraogo, S. Pali-Schöll, I. Papi, A. Passalacqua, G. Pedersen, S. Pépin, J.L. Pereira, A.M. Persico, M. Phillips, J. Picard, R. Pigearias, B. Pin, I. Pitsios, C. Pohl, W. Portejoie, F. Pozzi, A.C. Price, D. Puy, R. Pugin, B. Pulido Ross, R.E. Przemecka, M. Rabe, K.F. Raciborski, F. Reitsma, S. Ribeirinho, I. Rimmer, J. Rivero-Yeverino, D. Rizzo, J.A. Rizzo, M.C. Robalo-Cordeiro, C. Rodenas, F. Rodo, X. Rodriguez Gonzalez, M. Rodriguez-Mañas, L. Rolland, C. Rodrigues Valle, S. Roman Rodriguez, M. Romano, A. Rodriguez-Zagal, E. Rolla, G. Roller-Wirnsberger, R.E. Romano, M. Rosado-Pinto, J. Rosario, N. Sagara, H. Sastre-Dominguez, J. Scadding, G.K. Scichilone, N. Schmid-Grendelmeier, P. Serpa, F.S. Shamai, S. Sierra, M. Simons, F.E.R. Siroux, V. Skrindo, I. Solé, D. Somekh, D. Sondermann, M. Sova, M. Sorensen, M. Sorlini, M. Spranger, O. Stelmach, R. Stukas, R. Sunyer, J. Strozek, J. Szylling, A. Tebyriçá, J.N. Thibaudon, M. Trama, U. Triggiani, M. Suppli Ulrik, C. Urrutia-Pereira, M. Valenta, R. van Eerd, M. van Ganse, E. van Hague, M. Vandenplas, O. Vezzani, G. Vasankari, T. Vatrella, A. Verissimo, M.T. Viart, F. Viegi, M. Vicheva, D. Vontetsianos, T. Walker, S. Werfel, T. Westman, M. Williams, D.M. Williams, S. Wilson, N. Wright, J. Wroczynski, P. Yakovliev, P. Yawn, B.P. Yiallouros, P.K. Yusuf, O.M. Zar, H.J. Zernotti, M.E. Zubrinich, C. Zurkuhlen, A.

Subjects
animal structures
Abstract

Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional. © 2018 American Academy of Allergy, Asthma & Immunology

Published
2000

212. The Brussels Declaration: the need for change in asthma management

Author

Holgate, S., Bisgaard, H., Bjermer, L., Haahtela, T., Haughney, J., Horne, R., McIvor, A., Palkonen, S., Price, D.B., Thomas, M., Valovirta, E., Wahn, U., Holgate, S., Bisgaard, H., Bjermer, L., Haahtela, T., Haughney, J., Horne, R., McIvor, A., Palkonen, S., Price, D.B., Thomas, M., Valovirta, E., and Wahn, U.

Abstract

Asthma is a highly prevalent condition across Europe and numerous guidelines have been developed to optimise management. However, asthma can be neither cured nor prevented, treatment choices are limited and many patients have poorly controlled or uncontrolled asthma. The Brussels Declaration on Asthma, sponsored by The Asthma, Allergy and Inflammation Research Charity, was developed to call attention to the shortfalls in asthma management and to urge European policy makers to recognise that asthma is a public health problem that should be a political priority. The Declaration urges recognition and action on the following points: the systemic inflammatory component of asthma should be better understood and considered in assessments of treatment efficacy; current research must be communicated and responded to quickly; the European Medicines Agency guidance note on asthma should be updated; "real world" studies should be funded and results used to inform guidelines; variations in care across Europe should be addressed; people with asthma should participate in their own care; the impact of environmental factors should be understood; and targets should be set for improvement. The present paper reviews the evidence supporting the need for change in asthma management and summarises the ten key points contained in the Brussels Declaration Udgivelsesdato: 2008/12

Published
2008

214. Altered fibroblast repair function in COPD

Author

Hallgren, O., primary, Rolandsson, S., additional, Andersson-Sjöland, A., additional, Wieslander, E., additional, Dahlbäck, M., additional, Eriksson, L., additional, Bjermer, L., additional, Erjefält, J.E., additional, Löfdahl, C.G., additional, and Westergren-Thorsson, G., additional

Published
2013
Full Text
View/download PDF

215. Determinants of lung function and airway hyperresponsiveness in asthmatic children

Author

Bisgaard, H, Pedersen, S, Anhøj, J, Agertoft, L, Hedlin, G, Gulsvik, A, Bjermer, L, Carlsen, K H, Nordvall, L, Lundbäck, B, Wennergren, G, Werner, S, Bønnelykke, K, Weiss, S T, Bisgaard, H, Pedersen, S, Anhøj, J, Agertoft, L, Hedlin, G, Gulsvik, A, Bjermer, L, Carlsen, K H, Nordvall, L, Lundbäck, B, Wennergren, G, Werner, S, Bønnelykke, K, and Weiss, S T

Abstract

Background Asthma patients exhibit an increased rate of loss of lung function. Determinants to such decline are largely unknown and the modifying effect of steroid therapy is disputed. This cross-sectional study aimed to elucidate factors contributing to such decline and the possible modifying effect of steroid treatment. Methods We analyzed determinants of lung function and airway hyperresponsiveness (AHR) in a Scandinavian study of 2390 subjects from 550 families. Families were selected for the presence of two or more asthmatic children as part of a genetic study, Scandinavian Asthma Genetic Study (SAGA). Results The primary analysis studied the association between the lung function and delay of inhaled corticosteroids (ICS) after asthma diagnosis among asthmatic children and young adults with a history of regular ICS treatment (N=919). FEV1 percent predicted (FEV1% pred) was 0.25% lower per year of delay from diagnosis until treatment (p=0.039). This association was significantly greater in allergy skin prick test negative children. There was no significant influence of gender, age at asthma onset, or smoking. In the secondary analysis of the whole population of 2390 asthmatics and non-asthmatics, FEV1% pred was inversely related to having asthmatic siblings (−7.9%; p<0.0001), asthma diagnosis (−2.7%; p=0.0007), smoking (−3.5%; p=0.0027), and positive allergy skin prick test (−0.47% per test; p=0.012), while positively related to being of female gender (1.8%; p=0.0029). Risk of AHR was higher by having asthmatic siblings (OR 2.7; p<0.0001), being of female gender (OR 2.0; p<0.0001), and having asthma (OR 2.0; p<0.0001). Conclusions These data suggest that lung function is lower in asthmatics with delayed introduction of ICS therapy, smoking, and positive allergy skin prick test. Lung function is lower and AHR higher in female asthmatics and subjects with asthmatic siblings or established asthma.

Published
2007
Full Text
View/download PDF

216. Extracellular phospholipase A2 expression in sarcoidosis

Author

Andersen S, Bjermer L, Pål Kristian Selbo, Dalaker M, and Johansen B

Subjects
Adult, Biopsy, Enzyme-Linked Immunosorbent Assay, Muscle, Smooth, Middle Aged, Immunohistochemistry, Actins, Phospholipases A, Phospholipases A2, Sarcoidosis, Pulmonary, Bronchoscopy, Humans, RNA, Messenger, Extracellular Space, Bronchoalveolar Lavage Fluid, In Situ Hybridization, Aged
Abstract

This study was conducted in order to focus upon the Ca2- dependent secretory non-pancreatic phospholipase A2 (npPLA2) enzyme and its possible role in the pathophysiology of sarcoidosis. Serum samples were taken from 24 patients with sarcoidosis to determine the levels of npPLA2. Moreover, in another group of patients with active chest x-ray stage II and III sarcoidosis, bronchoscopy with bronchoalveolar lavage (BAL) and transbronchial lung biopsies (TBL) were taken. Highly significant increase of npPLA2 in serum was found in patients compared to controls (p0.001). Furthermore, those patients with stable and inactive disease and those who were under treatment with corticosteroids, tended to have lower values than those with active disease and those who were untreated. An intense accumulation of npPLA2 was found in smooth muscle tissue in lung biopsy specimens, in close connection with fibroblast accumulation and deposition of collagen. These cells also stained positive for alpha-smooth muscle actin (alpha-SMA). In addition, when using the technique of in situ hybridization, expression of npPLA2-mRNA was found in the fibroblast layer surrounding the epitheloid cell granulomas. These fibroblasts did not stain positive for alpha-SMA. Our data suggest that npPLA2 is actively involved, and has an important role, in the pathophysiology of sarcoidosis.

Published
1996

236. Temperature-controlled Laminar Airflow (TLA) in symptomatic severe asthma - a post hoc analysis of severe exacerbations, quality of life and health economics.

Author

Chauhan, A J, Eriksson, G, Storrar, W, Brown, T, Peterson, S, Radner, F, D'Cruz, L G, Miller, P, and Bjermer, L

Abstract

Purpose: Uncontrolled severe asthma constitutes a major economic burden to society. Add-ons to standard inhaled treatments include inexpensive oral corticosteroids and expensive biologics. Nocturnal treatment with Temperature-controlled Laminar Airflow (TLA; Airsonett®) could be an effective, safe and cheaper alternative. The potential of TLA in reducing severe asthma exacerbations was addressed in a recent randomised placebo-controlled trial (RCT) in patients with severe asthma (Global Initiative for Asthma (GINA) step 4/5), but the results were inconclusive. We re-analysed the RCT with severe exacerbations stratified by the level of baseline asthma symptoms and Quality of Life.Methods: More uncontrolled patients, defined by Asthma Control Questionnaire 7 (ACQ7) > 3, EuroQoL 5-Dimension Questionnaire Visual Analogue Scale (EQ5D-VAS) ≤ 65 and Asthma Quality of Life Questionnaire (AQLQ) ≤ 4 were selected for re-analysis. The rates of severe asthma exacerbations, changes in QoL and health-economics were analysed and compared between TLA and placebo.Results: The study population included 226 patients (113 TLA / 113 placebo.) The rates of severe asthma exacerbations were reduced by 33, 31 and 25% (p = 0.083, 0.073, 0.180) for TLA compared to placebo, dependent on selected control measures (ACQ7, EQ5D-VAS, AQLQ, respectively). For patients with less control defined by AQLQ≤4, the difference in mean AQLQ0-12M between TLA and placebo was 0.31, 0.33, 0.26 (p = 0.085, 0.034, 0.150), dependent on selected covariate (AQLQ, EQ5D-VAS, ACQ7, respectively). For patients with poor control defined by ACQ7 > 3, the difference in EQ5D-5 L utility scores between TLA and placebo was significant at 9 and 12 months with a cost-effective ICER. The results from the original study did not demonstrate these differences.Conclusion: This post hoc analysis demonstrated an effect of TLA over placebo on severe exacerbations, asthma control and health economics in a subgroup of patients with more symptomatic severe allergic asthma. The results are consistent with the present recommendations for TLA. However, these differences were not demonstrated in the full study. Several explanations for the different outcomes have been outlined, which should be addressed in future studies.Funding: NIHR Health Technology Assessment Programme and Portsmouth Hospitals NHS Trust. [ABSTRACT FROM AUTHOR]

Published
2022
Full Text
View/download PDF

237. The Brussels Declaration: the need for change in asthma management

Author

Holgate, S., primary, Bisgaard, H., additional, Bjermer, L., additional, Haahtela, T., additional, Haughney, J., additional, Horne, R., additional, McIvor, A., additional, Palkonen, S., additional, Price, D. B., additional, Thomas, M., additional, Valovirta, E., additional, and Wahn, U., additional

Published
2008
Full Text
View/download PDF

238. Treatment of exercise-induced asthma, respiratory and allergic disorders in sports and the relationship to doping: Part II of the report from the Joint Task Force of European Respiratory Society (ERS) and European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN

Author

Carlsen, K. H., primary, Anderson, S. D., additional, Bjermer, L., additional, Bonini, S., additional, Brusasco, V., additional, Canonica, W., additional, Cummiskey, J., additional, Delgado, L., additional, Del Giacco, S. R., additional, Drobnic, F., additional, Haahtela, T., additional, Larsson, K., additional, Palange, P., additional, Popov, T., additional, and van Cauwenberge, P., additional

Published
2008
Full Text
View/download PDF

239. Exercise-induced asthma, respiratory and allergic disorders in elite athletes: epidemiology, mechanisms and diagnosis: Part I of the report from the Joint Task Force of the European Respiratory Society (ERS) and the European Academy of Allergy and Clinical Immunology (EAACI) in cooperation with GA2LEN

Author

Carlsen, K. H., primary, Anderson, S. D., additional, Bjermer, L., additional, Bonini, S., additional, Brusasco, V., additional, Canonica, W., additional, Cummiskey, J., additional, Delgado, L., additional, Del Giacco, S. R., additional, Drobnic, F., additional, Haahtela, T., additional, Larsson, K., additional, Palange, P., additional, Popov, T., additional, and van Cauwenberge, P., additional

Published
2008
Full Text
View/download PDF

240. Determinants of lung function and airway hyperresponsiveness in asthmatic children

Author

Bisgaard, H., primary, Pedersen, S., additional, Anhøj, J., additional, Agertoft, L., additional, Hedlin, G., additional, Gulsvik, A., additional, Bjermer, L., additional, Carlsen, K.H., additional, Nordvall, L., additional, Lundbäck, B., additional, Wennergren, G., additional, Werner, S., additional, Bønnelykke, K., additional, and Weiss, S.T., additional

Published
2007
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results